Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Finnish (OMX) Healthcare Sector Analysis

UpdatedAug 09, 2026
DataAggregated Company Financials
Companies13
  • 7D0.9%
  • 3M16.9%
  • 1Y9.6%
  • YTD6.8%

The Healthcare industry has been flat over the last week, but Biohit Oyj has lost 4.6%. As for the the longer term, the industry is up 9.6% over the past 12 months. As for the next few years, earnings are expected to grow by 11% per annum.

Sector Valuation and Performance

Has the Finnish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 10 Aug 2026€13.6b€5.9b€621.6m16.9x21.9x2.3x
Wed, 08 Jul 2026€12.3b€5.9b€576.3m17.3x21.3x2.1x
Fri, 05 Jun 2026€11.9b€5.9b€576.3m16.8x20.7x2x
Sun, 03 May 2026€11.8b€5.9b€573.9m16.2x20.6x2x
Tue, 31 Mar 2026€12.0b€5.9b€561.2m15.7x21.4x2x
Thu, 26 Feb 2026€12.2b€5.8b€551.8m14x22.2x2.1x
Sat, 24 Jan 2026€12.9b€5.6b€367.7m22.2x35x2.3x
Mon, 22 Dec 2025€11.7b€5.6b€367.7m23.9x31.8x2.1x
Wed, 19 Nov 2025€11.2b€5.6b€367.7m22.2x30.6x2x
Fri, 17 Oct 2025€12.7b€5.7b€419.6m20.9x30.3x2.2x
Sun, 14 Sep 2025€12.8b€5.7b€420.9m19.1x30.4x2.3x
Tue, 12 Aug 2025€12.5b€5.7b€426.3m19x29.4x2.2x
Thu, 10 Jul 2025€12.7b€5.5b€392.7m18.3x32.4x2.3x
Sat, 07 Jun 2025€12.2b€5.5b€392.7m18.6x31.1x2.2x
Mon, 05 May 2025€11.4b€5.5b€391.6m19.1x29.1x2.1x
Wed, 02 Apr 2025€11.1b€5.4b€364.7m20.2x30.5x2x
Fri, 28 Feb 2025€10.9b€5.4b€370.9m20.2x29.3x2x
Sun, 26 Jan 2025€10.5b€5.2b€274.3m24.9x38.2x2x
Tue, 24 Dec 2024€9.0b€5.2b€274.3m19.8x32.9x1.7x
Thu, 21 Nov 2024€9.3b€5.2b€274.3m20.2x33.9x1.8x
Sat, 19 Oct 2024€10.0b€5.0b€144.2m25.4x69.2x2x
Mon, 16 Sep 2024€9.8b€5.0b€143.6m24.6x68.3x2x
Wed, 14 Aug 2024€9.4b€5.0b€141.7m26.6x66.3x1.9x
Fri, 12 Jul 2024€8.9b€4.9b€115.7m27.4x76.5x1.8x
Sun, 09 Jun 2024€8.5b€4.9b€115.7m28.5x73.2x1.7x
Tue, 07 May 2024€7.9b€4.9b€118.1m27.3x67x1.6x
Thu, 04 Apr 2024€7.3b€4.8b€108.0m30.8x67.6x1.5x
Sat, 02 Mar 2024€7.7b€4.8b€107.9m27.7x71.5x1.6x
Mon, 29 Jan 2024€8.7b€4.8b€135.4m33.6x64.5x1.8x
Wed, 27 Dec 2023€8.1b€4.8b€135.4m31.8x59.6x1.7x
Fri, 24 Nov 2023€7.6b€4.8b€135.4m30.1x56.4x1.6x
Sun, 22 Oct 2023€7.5b€5.0b€270.4m27.2x27.9x1.5x
Tue, 19 Sep 2023€7.6b€5.0b€269.6m27.7x28.2x1.5x
Thu, 17 Aug 2023€7.3b€5.0b€276.3m23.3x26.5x1.5x
Price to Earnings Ratio

26.5x


Total Market Cap: €7.3bTotal Earnings: €276.3mTotal Revenue: €5.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Finnish Healthcare Sector Price to Earnings3Y Average 41.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Finnish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 21.9x which is lower than its 3-year average PE of 41.6x.
  • The 3-year average PS ratio of 1.9x is lower than the industry's current PS ratio of 2.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 5.9% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Finnish Healthcare sector?

FI Market0.55%
Healthcare0.88%
Life Sciences14.72%
Medical Equipment7.23%
Healthcare Services0.88%
Pharma0.49%
Biotech0%0
Healthtech-3.16%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 202x.
    • Analysts are expecting annual earnings growth of 30.0%, which is higher than its past year's earnings growth of 10.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Life Sciences industry, expecting annual earnings growth of 50% over the next 5 years.
  • In contrast, the Pharma industry is expected to see its earnings grow by 8.6% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ORNBV Orion Oyj€81.500.5%
+€56.3m		24.6%PE19.6x
REG1V Revenio Group Oyj€13.5611.0%
+€35.7m		-44.2%PE23x
NANOFH Nanoform Finland Oyj€0.9914.7%
+€10.9m		1.9%PS15.7x
TTALO Terveystalo Oyj€7.610.5%
+€5.1m		-27.9%PE14.2x
PIHLIS Pihlajalinna Oyj€10.502.1%
+€4.9m		-32.3%PE9.7x

Latest News

BIOBV
€2.68
Biohit Oyj
7D
-4.6%
1Y
-6.9%
Analysis Article • Aug 08

Results: Biohit Oyj Beat Earnings Expectations And Analysts Now Have New Forecasts

Shareholders might have noticed that Biohit Oyj ( HEL:BIOBV ) filed its half-year result this time last week. The early...
ORNBV
€81.50
Orion Oyj
7D
0.5%
1Y
24.6%
Narrative Update • Aug 07

ORNBV: Fair Outlook Will Balance New Partnerships And Drug Pipeline Execution Risks

Analysts have nudged their average price target for Orion Oyj higher to about €76.67 from roughly €74.33, reflecting updated views on discount rates, revenue growth assumptions and profit margins following recent research. Analyst Commentary Recent research on Orion Oyj points to a more mixed stance among covering analysts.
BRETEC
€0.023
Bioretec Oy
7D
7.5%
1Y
-98.7%
PIHLIS
€10.50
Pihlajalinna Oyj
7D
2.1%
1Y
-32.3%
Analysis Article • Jul 27

Pihlajalinna Oyj Just Missed Earnings - But Analysts Have Updated Their Models

As you might know, Pihlajalinna Oyj ( HEL:PIHLIS ) last week released its latest quarterly, and things did not turn out...
AIFORIA
€1.10
Aiforia Technologies Oyj
7D
-3.2%
1Y
-66.9%
TTALO
€7.61
Terveystalo Oyj
7D
0.5%
1Y
-27.9%
Analysis Article • Jul 22

Terveystalo Oyj Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

As you might know, Terveystalo Oyj ( HEL:TTALO ) last week released its latest second-quarter, and things did not turn...
ORIOLA
€0.91
Oriola Oyj
7D
1.4%
1Y
-16.5%
Analysis Article • Jul 22

Earnings Miss: Oriola Oyj Missed EPS And Analysts Are Revising Their Forecasts

Last week saw the newest quarterly earnings release from Oriola Oyj ( HEL:ORIOLA ), an important milestone in the...
MODU
€1.11
Modulight Oyj
7D
5.7%
1Y
-7.2%
Narrative Update • Jun 25

MODU: Revised Assumptions And Guidance Will Shape Future Earnings Quality

The analyst price target for Modulight Oyj has been revised from €1.30 to €1.20 as analysts now apply a slightly lower discount rate along with more conservative assumptions for revenue growth, profit margins and future P/E levels. What’s in the News for Modulight Oyj Modulight Oyj has scheduled a board meeting for May 4, 2026, with an agenda focused on electing members of its Remuneration Committee.
REG1V
€13.56
Revenio Group Oyj
7D
11.0%
1Y
-44.2%
Narrative Update • Jun 16

REG1V: Street Downgrades Will Set Up Future Upside Repricing

Analysts maintained their fair value estimate for Revenio Group Oyj at €18.0. A slightly lower discount rate and a marginally reduced future P/E assumption reflect more cautious sentiment following recent downgrades in Street research. Analyst Commentary on Revenio Group Oyj Recent Street research on Revenio Group Oyj has turned more cautious, with multiple downgrades pointing to concerns that contrast with the fair value estimate being held at €18.0. For you as an investor, the key is to distinguish where analysts still see support for the valuation from where they see growing execution and growth risks.
NANOFH
€0.99
Nanoform Finland Oyj
7D
14.7%
1Y
1.9%